Application of compound or medicinal derivative thereof in inhibition of AIM2 protein activity

Abstract

The invention belongs to the technical field of protein inhibition drugs, and particularly relates to application of a compound or a medicinal derivative thereof in inhibition of AIM2 protein activity. Compared with a traditional broad-spectrum immunomodulator, the compound has a strong targeting effect and is more accurate, faster, more effective, safer and more stable; the binding force between the antibody and AIM2 human protein and the binding force between the antibody and AIM2 mouse protein are very strong, and the binding constants are as high as 1.029 E <-5 > M and 1.033 E <-5 > M respectively; compared with a traditional biological inhibitor, the compound is easy to store, stable in activity, small in molecular weight, low in production cost and easy to absorb.

Description

technical field [0001] The invention belongs to the technical field of protein inhibitory drugs, and particularly relates to the use of a compound or a medicinal derivative thereof in inhibiting the activity of AIM2 protein. Background technique [0002] Psoriasis is a global, refractory, high-morbidity inflammatory immune disease that cannot be completely cured under the current medical level. There are many clinical treatments for psoriasis, most of which try to relieve symptoms through extensive suppression of the immune system, such as the use of hormones and immunosuppressants, as well as some physical therapy and traditional Chinese medicine. However, broad-spectrum symptomatic treatment is often ineffective, and it is easy to cause repeated disease or other system damage. In recent years, the development of precision medicine for psoriasis has made up for the deficiencies of traditional treatment options to a certain extent. The research and development of many biolo...

AI Technical Summary

Problems solved by technology

However, it has the same drawbacks as traditional treatment options. All the biological agents for psoriasis currently on the market are still symptomatic treatments that reduce the phenotype by blocking the efficacy of downstream effector molecules. Stop using biological agents for more than Six months, the risk of psoriasis recurrence will be greatly increased

In addition, biological agents are expensive. Due to the need for long-term maintenance medication, if the effect weakens midway, multiple biological agents must be used in combination, which brings a greater economic burden to patients.

[0004] In summary, the drugs currently used for the treatment of psoriasis can be roughly divided into two main types: broad-spectrum immunomodulatory drugs and targeted drugs; the long-term effect of broad-spectrum traditional immunomodulators is not ideal, and biological agents The representative targeted drugs make up for the lack of efficacy of traditional drugs to a certain extent, but biological agents are expensive and have relatively high applicable standards

There are fewer other types of targeted drugs (natural small molecules or artificial compounds) for psoriasis on the market, and almost all of them target the downstream effector pathways in the pathogenesis of psoriasis. The influence of the initial pathway upstream and its upstream is weak, and the long-term effect of this symptomatic treatment may be poor compared with the therapy that interferes with the factors upstream of the psoriatic inflammatory pathway

Images